Humacyte: Positive News For Symvess At Last, But Long-Term Threats Persist [Seeking Alpha]
Humacyte, Inc. (HUMA)
Company Research
Source: Seeking Alpha
Symvess is the only FDA-approved human-derived bioengineered blood vessel, but Q3 revenue was just $700k, and uptake remains limited. HUMA's funding runway is constrained, with recent capital raises offset by high R&D spending; further dilution or cost cuts may be needed. Key 2026 catalysts are dialysis data readouts and BLA submissions, not the recent DoD news, given ongoing risks and modest near-term sales. Looking for more investing ideas like this one? Get them exclusively at Haggerston BioHealth. Learn More » We Are/DigitalVision via Getty Images Investment Overview The stock of Durham, North Carolina-based biotech Humacyte, Inc. ( HUMA ) is buoyant today—up ~28% at the time of writing, with a share price of $1.2 and a market cap of $236m—on news that, according to a More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving
Show less
Read more
Impact Snapshot
Event Time:
HUMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HUMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HUMA alerts
High impacting Humacyte, Inc. news events
Weekly update
A roundup of the hottest topics
HUMA
News
- Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at BTIG Research.MarketBeat
- Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.MarketBeat
- Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood VesselsGlobeNewswire
- Humacyte (NASDAQ:HUMA) had its price target lowered by analysts at Benchmark Co. from $11.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury ComplicationsGlobeNewswire
HUMA
Earnings
- 11/12/25 - Beat
HUMA
Sec Filings
- 1/9/26 - Form SCHEDULE
- 12/16/25 - Form 8-K
- 12/16/25 - Form 424B5
- HUMA's page on the SEC website